{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:49Z","timestamp":1792801969403,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370393"],"award-info":[{"award-number":["81370393"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Funds for the Central Universities of Central South University","award":["2016zzts545"],"award-info":[{"award-number":["2016zzts545"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12944-016-0352-y","type":"journal-article","created":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T07:19:20Z","timestamp":1477120760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism"],"prefix":"10.1186","volume":"15","author":[{"given":"Mengdie","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,22]]},"reference":[{"key":"352_CR1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med"},{"key":"352_CR2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"J Bosch","year":"2012","unstructured":"ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309\u201318.","journal-title":"N Engl J Med"},{"key":"352_CR3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345\u201352.","journal-title":"Nat Genet"},{"key":"352_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22\u201331.","journal-title":"N Engl J Med"},{"key":"352_CR5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341.","journal-title":"N Engl J Med"},{"key":"352_CR6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","volume":"114","author":"EMM Ooi","year":"2008","unstructured":"Ooi EMM, Barrett PHR, Chan DC, et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114:611\u201324.","journal-title":"Clin Sci (Lond)"},{"key":"352_CR7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1194\/M900346-JLR200","volume":"51","author":"M Sundaram","year":"2010","unstructured":"Sundaram M, Zhong S, Bou Khalil M, et al. Expression of apolipoprotein CIII in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2010;51:150\u201361.","journal-title":"J Lipid Res"},{"key":"352_CR8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1871529X11202020133","volume":"12","author":"Z Yao","year":"2012","unstructured":"Yao Z. Human apolipoprotein C-III: a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins. Cardiovasc Hematol Disord Drug Targets. 2012;12:133\u201340.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"352_CR9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1161\/CIRCULATIONAHA.111.056986","volume":"124","author":"CO Mendivil","year":"2011","unstructured":"Mendivil CO, Rimm EB, Furtado J, et al. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation. 2011;124:2065\u201372.","journal-title":"Circulation"},{"key":"352_CR10","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1373\/clinchem.2008.103234","volume":"54","author":"PG Scheffer","year":"2008","unstructured":"Scheffer PG, Teerlink T, Dekker JM, et al. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn study. Clin Chem. 2008;54:1325\u201330.","journal-title":"Clin Chem"},{"key":"352_CR11","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1038\/ncomms10353","volume":"7","author":"S Valleix","year":"2016","unstructured":"Valleix S, Verona G, Jourde-Chiche N, et al. D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nat Commun. 2016;7:10353.","journal-title":"Nat Commun"},{"key":"352_CR12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","volume":"322","author":"TI Pollin","year":"2008","unstructured":"Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702\u20135.","journal-title":"Science"},{"key":"352_CR13","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/CIRCRESAHA.114.301174","volume":"114","author":"GJ Randolph","year":"2014","unstructured":"Randolph GJ. Mechanisms That Regulate Macrophage Burden in Atherosclerosis. Circ Res. 2014;114:1757\u201371.","journal-title":"Circ Res"},{"key":"352_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.ATV.0000249620.68705.0d","volume":"27","author":"A Kawakami","year":"2007","unstructured":"Kawakami A, Aikawa M, Nitta N, et al. Apolipoprotein CIII-Induced THP-1 Cell Adhesion to Endothelial Cells Involves Pertussis Toxin-Sensitive G Protein- and Protein Kinase C-Mediated Nuclear Factor- \u03baB Activation. Arterioscler Thromb Vasc Biol. 2007;27:219\u201325.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"352_CR15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","volume":"114","author":"A Kawakami","year":"2006","unstructured":"Kawakami A, Aikawa M, Alcaide P, et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114:681\u20137.","journal-title":"Circulation"},{"key":"352_CR16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/eurheartj\/ehs271","volume":"34","author":"C Zheng","year":"2013","unstructured":"Zheng C, Azcutia V, Aikawa E, et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J. 2013;34:615\u201324.","journal-title":"Eur Heart J"},{"key":"352_CR17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cvr\/cvv192","volume":"107","author":"H Li","year":"2015","unstructured":"Li H, Han Y, Qi R, et al. Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. Cardiovasc Res. 2015;107:579\u201389.","journal-title":"Cardiovasc Res"},{"key":"352_CR18","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMra1011670","volume":"364","author":"JI Borissoff","year":"2011","unstructured":"Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364:1746\u201360.","journal-title":"N Engl J Med"},{"key":"352_CR19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1538-7836.2009.03720.x","volume":"8","author":"O Olivieri","year":"2010","unstructured":"Olivieri O, Martinelli N, Girelli D, et al. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. J Thromb Haemost. 2010;8:463\u201371.","journal-title":"J Thromb Haemost"},{"key":"352_CR20","doi-asserted-by":"crossref","first-page":"e000440","DOI":"10.1161\/JAHA.113.000440","volume":"2","author":"O Olivieri","year":"2013","unstructured":"Olivieri O, Martinelli N, Baroni M, et al. Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele. J Am Heart Assoc. 2013;2:e000440.","journal-title":"J Am Heart Assoc"},{"key":"352_CR21","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","volume":"128","author":"RS Rosenson","year":"2013","unstructured":"Rosenson RS, Brewer Jr HB, Ansell B, et al. Translation of high- density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128:1256\u201367.","journal-title":"Circulation"},{"key":"352_CR22","doi-asserted-by":"crossref","first-page":"e000232","DOI":"10.1161\/JAHA.111.000232","volume":"1","author":"MK Jensen","year":"2012","unstructured":"Jensen MK, Rimm EB, Furtado JD, et al. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc. 2012;1:e000232.","journal-title":"J Am Heart Assoc"},{"key":"352_CR23","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1194\/jlr.M042333","volume":"55","author":"B Talayero","year":"2014","unstructured":"Talayero B, Wang L, Furtado J, et al. Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. J Lipid Res. 2014;55:2167\u201377.","journal-title":"J Lipid Res"},{"key":"352_CR24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1476-511X-11-162","volume":"11","author":"PY Chang","year":"2012","unstructured":"Chang PY, Lee CM, Hsu HC, et al. Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: The Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan. Lipids Health Dis. 2012;11:162.","journal-title":"Lipids Health Dis"},{"key":"352_CR25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12944-015-0129-8","volume":"14","author":"X Xiong","year":"2015","unstructured":"Xiong X, Liu H, Hua L, et al. The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids Health Dis. 2015;14:127.","journal-title":"Lipids Health Dis"},{"issue":"8","key":"352_CR26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","volume":"127","author":"M Riwanto","year":"2013","unstructured":"Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary disease: role of high-density lipoprotein-proteome remodeling. Circulation. 2013;127(8):891\u2013904.","journal-title":"Circulation"},{"key":"352_CR27","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2010111144","volume":"22","author":"M Holzer","year":"2011","unstructured":"Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia Alters HDL Composition and Function. J Am Soc Nephrol. 2011;22:1631\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"352_CR28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/ATVBAHA.110.220723","volume":"31","author":"S Caron","year":"2011","unstructured":"Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31:513\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"352_CR29","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00018-013-1442-x","volume":"71","author":"Y Shi","year":"2014","unstructured":"Shi Y, Yang G, Yu J, Yu L, Westenbroek R, Catterall WA, Juntti-Berggren L, Berggren PO, Yang SN. Apolipoprotein CIII hyperactivates \u03b2 cell CaV1 channels through SR-BI\/\u03b21 integrin-dependent coactivation of PKA and Src. Cell Mol Life Sci. 2014;71:1289\u2013303.","journal-title":"Cell Mol Life Sci"},{"key":"352_CR30","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1073\/pnas.1019553108","volume":"108","author":"R Holmberg","year":"2011","unstructured":"Holmberg R, Refai E, H\u00f6\u00f6g A, et al. Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci U S A. 2011;108:10685\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"352_CR31","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1161\/ATVBAHA.115.305415","volume":"35","author":"A Qamar","year":"2015","unstructured":"Qamar A, Khetarpal SA, Khera AV, et al. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol. 2015;35:1880\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"352_CR32","doi-asserted-by":"crossref","first-page":"E2611","DOI":"10.1073\/pnas.1423849112","volume":"119","author":"K Avall","year":"2015","unstructured":"Avall K, Ali Y, Leibiger IB, et al. Apolipoprotein CIII links islet insulin resistance to \u03b2-cell failure in diabetes. Proc Natl Acad Sci U S A. 2015;119:E2611\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"352_CR33","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1210\/en.2010-1422","volume":"152","author":"J St\u00f8rling","year":"2011","unstructured":"St\u00f8rling J, Juntti-Berggren L, Olivecrona G, et al. Apolipoprotein CIII Reduces Proinflammatory Cytokine-Induced Apoptosis in Rat Pancreatic Islets via the Akt Prosurvival Pathway. Endocrinology. 2011;152:3040\u20138.","journal-title":"Endocrinology"},{"key":"352_CR34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1194\/jlr.R024190","volume":"53","author":"RS Rosenson","year":"2012","unstructured":"Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012;53:1767\u201382.","journal-title":"J Lipid Res"},{"key":"352_CR35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1242\/bio.201410900","volume":"4","author":"X Han","year":"2015","unstructured":"Han X, Wang T. Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFkB pathways. Biology Ope. 2015;4:661\u20135.","journal-title":"Biology Ope"},{"key":"352_CR36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell III TA, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479\u201390.","journal-title":"Circ Res"},{"key":"352_CR37","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373:438\u201347.","journal-title":"N Engl J Med"},{"key":"352_CR38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1194\/jlr.M066399","volume":"57","author":"X Yang","year":"2016","unstructured":"Yang X, Lee SR, Choi YS, et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: activity, apolipoprotein C3 cardiovascular In disease: The Communities Phase 2 randomized trial results. J Lipid Res. 2016;57:706\u201313.","journal-title":"J Lipid Res"},{"key":"352_CR39","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200\u20136.","journal-title":"N Engl J Med"},{"key":"352_CR40","doi-asserted-by":"crossref","first-page":"17259","DOI":"10.1038\/srep17259","volume":"5","author":"M Rahimi","year":"2015","unstructured":"Rahimi M, Ng EP, Bakhtiari K, et al. Zeolite Nanoparticles for Selective Sorption of Plasma Proteins. Sci Rep. 2015;5:17259.","journal-title":"Sci Rep"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-016-0352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T18:58:58Z","timestamp":1568487538000},"score":1,"resource":{"primary":{"URL":"http:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-016-0352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,22]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1186\/s12944-016-0352-y","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,22]]},"article-number":"184"}}